Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
$0.09 → $0.09 · observed estimates
Eva Live Inc (GOAI)
NASDAQInformation TechnologySoftware - InfrastructureSnapshot 2026-11-04
$0.60-25.88%
Close 2026-11-05 · 1-day change
NASDAQInformation TechnologySoftware - InfrastructureSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for GOAI yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Revenue growth from AI platform launches and acquisitions | Eva Live is expanding with new AI platforms and acquisitions. | Intact | Revenue growth stalls or declines over next 4 quarters | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
$0.09 → $0.09 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth story in drone and defense technology, not an established compounder. The thesis is in a watch state, and recent performance is below its industry cohort even though it has not freshly broken.
The evidence labels GOAI cheap versus peers, but the valuation model has low confidence and shows a negative expectations gap. The market appears to reflect weak expectations, while the low fragility reading does not remove the business risks.
Near term, results may remain pressured: the company is loss-making, management is rated volatile, and recent financial performance is neutral. Acquisitions, improving operating income, and raising capital through equity and convertible notes are priorities still marked for watching; a recent legal or regulatory event adds uncertainty.
Over the multi-year view, the thesis depends on whether acquisitions can support the business and operating income improves without funding needs becoming a greater strain. Near term, rate cuts or steadier results and guidance from major technology companies could help the sector backdrop, while GDP growth below 2% would be a headwind.
For the next 1 to 3 years, GOAI remains a high-risk, loss-making story with uncertain execution and funding needs, despite a valuation label of cheap versus peers. The thesis depends on operating progress and how the company handles these risks. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Eva Live Inc's published investment case. The stated target is Debt levels remain manageable without impairing operations next 4 quarters. |
| Intact |
| Debt levels rise to impair liquidity or increase financial risk materially |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating income improves from recent losses | Management aims to improve operating income despite recent losses. | Broken | Operating income remains below -$9.11M over next 4 quarters | Operating income: $-862,213 FY2026-Q2; GAAP. Published target: Operating income improves to better than -$9.11M next 4 quarters. Target period is not explicitly aligned with this observation. Aug 3, 2026-862,213 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.03B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-15 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-10-16 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-10-17 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-10-18 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-10-19 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-10-20 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-10-21 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-10-22 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-10-23 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-10-24 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-10-25 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-10-26 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-10-27 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-10-28 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-10-29 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-10-30 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-10-31 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-11-01 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-11-02 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-11-03 | $0.09 | $30,000,000 | 1 / 1 |
| 2026-11-04 | $0.09 | $30,000,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.